Frontier Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Frontier Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,078	Closed	-$566K	–	374
2019 Q1	$566K	Hold	3,078	–	–	0.08%	203
2018 Q4	$510K	Hold	3,078	–	–	0.08%	201
2018 Q3	$593K	Sell	3,078 -1,000	-25%	-$178K	0.06%	205
2018 Q2	$693K	Hold	4,078	–	–	0.1%	175
2018 Q1	$665K	Sell	4,078 -1,000	-20%	-$163K	0.09%	187
2017 Q4	$761K	Hold	5,078	–	–	0.12%	158
2017 Q3	$772K	Sell	5,078 -1,000	-16%	-$151K	0.11%	173
2017 Q2	$783K	Hold	6,078	–	–	0.12%	173
2017 Q1	$665K	Hold	6,078	–	–	0.1%	190
2016 Q4	$448K	Buy	+6,078	New	+$495K	0.07%	231

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Frontier Wealth Management's VRTX Position: Q2 2019 in Review

Frontier Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 3,078 shares — an estimated $566K sold.

Frontier Wealth Management first reported a position in VRTX in Q4 2016 and held it in 10 quarters. The position peaked at $783K in Q2 2017. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Frontier Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Frontier Wealth Management sold 3,078 Vertex Pharmaceuticals shares in Q2 2019, an estimated $566K.
Frontier Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 10 quarters.
Frontier Wealth Management's Vertex Pharmaceuticals position peaked at $783K in Q2 2017.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Frontier Wealth Management's 13F filing for Q2 2019, filed 16 Aug 2019.